The central secondary endpoint, hepatic fat content, was met at 16 weeks post treatment initiation, with a highly significant reduction compared to placebo in all resmetirom arms.
← all excerpts
Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease.
1
—
—